Psyched: $100M For MDMA Therapy, VA Funds, 2024 Watchlist, Reform Updates And More – ATAI Life Sciences (NASDAQ:ATAI), Clearmind Medicine (NASDAQ:CMND)

Psychedelics Developer Secures $100M In Series A Funding, Will Support MDMA Approval To Treat PTSD

MAPS Public Benefit Corporation, a subsidiary of the Multidisciplinary Association for Psychedelic Studies (MAPS), has recently secured over $100 million in a Series A private stock sale. The funding will be used to support the final stages of its application for regulatory approval to sell MDMA, also known as ecstasy, as a treatment for post-traumatic stress disorder (PTSD).

MAPS has been incubating the only psychedelic-assisted therapy research program that has successfully completed two Phase 3 studies and submitted a New Drug Application to the FDA. This milestone funding will help accelerate the approval process and bring MDMA therapy for PTSD closer to legalization in the US and worldwide.

Veterans Affairs, After Decades, Will Fund Psychedelic Research For Vets With PTSD And Depression

The U.S. Department of Veterans Affairs (VA) has taken a groundbreaking step by launching new studies on using psychedelic compounds to treat post-traumatic stress disorder (PTSD) and depression among military veterans. This marks the first such research conducted by the VA since the 1960s.

The new VA-backed effort will focus on investigating the effectiveness and safety of using MDMA and psilocybin-augmented psychotherapy in veterans. This research initiative represents a significant shift in the VA’s approach to mental health treatment and highlights the growing recognition of the potential benefits of psychedelic-assisted therapies.

30 Psychedelics Executives, Scientists & Influencers To Watch In 2024 And Beyond

The field of psychedelic medicine is rapidly evolving, with key players and influential figures driving innovation and acceptance worldwide. This article highlights a list of 30 standout individuals who are making significant contributions to the field. These individuals come from diverse backgrounds, including scientists, investors, advocates, publicists, journalists, and policy reformers. Their work collectively underscores the global scope of the mental health movement centered on psychedelic therapy.

Psychedelics Reform Update: Policies Move Forward In Thirteen States On Fed And Local Levels

In parallel with recent federal decisions, state-level psychedelics policy reform is gaining momentum throughout the country. Thirteen states, including Arizona, California, Illinois, Indiana, Massachusetts, Missouri, Nevada, New Hampshire, New York, Rhode Island, Virginia, Washington, and Wisconsin, are making progress in advancing policies related to psychedelics. These developments highlight the shifting attitudes towards psychedelic substances and the increasing recognition of their potential therapeutic benefits.

Highest Trading Psychedelics Stocks Friday, Jan. 12 At Close

Several psychedelics stocks have shown promising performance in the market. COMPASS Pathways, GH Research, Incannex Healthcare, Mind Medicine (MindMed), Atai Life Sciences, Bright Minds Biosciences, Silo Pharma, Seelos Therapeutics, Clearmind Medicine, and Enveric Biosciences are among the highest trading psychedelics stocks as of Friday, January 12. These companies are actively involved in research and development efforts to bring psychedelic therapies to market.

In conclusion, the field of psychedelic medicine is gaining significant attention and support. With increased funding, research initiatives, and policy reforms, the potential benefits of psychedelic-assisted therapies for mental health conditions like PTSD and depression are being increasingly recognized. The progress made by MAPS, the VA, and various other organizations and individuals is paving the way for a new era of mental health treatment.

Leave a Reply

Your email address will not be published. Required fields are marked *